Laura Sepp-Lorenzino - Jan 8, 2024 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Signature
James Basta, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Jan 8, 2024
Transactions value $
-$65,682
Form type
4
Date filed
1/10/2024, 04:15 PM
Previous filing
Jan 5, 2024
Next filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Sale -$46.1K -1.61K -3.48% $28.66 44.6K Jan 8, 2024 Direct F1, F2
transaction NTLA Common Stock Sale -$19.6K -667 -1.5% $29.38 43.9K Jan 8, 2024 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.16 to $29.06, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 8, 2024 at each separate price.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.19 to $29.63, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 8, 2024 at each separate price.